169 related articles for article (PubMed ID: 37328158)
21. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
22. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.
Luyten K; Van Loy T; Cawthorne C; Deroose CM; Schols D; Bormans G; Cleeren F
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683912
[TBL] [Abstract][Full Text] [Related]
23. Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.
Trotta AM; Aurilio M; D'Alterio C; Ieranò C; Di Martino D; Barbieri A; Luciano A; Gaballo P; Santagata S; Portella L; Tomassi S; Marinelli L; Sementa D; Novellino E; Lastoria S; Scala S; Schottelius M; Di Maro S
J Med Chem; 2021 Mar; 64(6):3449-3461. PubMed ID: 33660512
[TBL] [Abstract][Full Text] [Related]
24. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
25. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
26. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
27. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
28.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
29. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
30. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
32. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.
Gourni E; Waser B; Clerc P; Fourmy D; Reubi JC; Maecke HR
J Nucl Med; 2014 Jun; 55(6):976-82. PubMed ID: 24744444
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
34. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
35. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.
Nimmagadda S; Pullambhatla M; Pomper MG
J Nucl Med; 2009 Jul; 50(7):1124-30. PubMed ID: 19525448
[TBL] [Abstract][Full Text] [Related]
36. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
37. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.
Lesniak WG; Sikorska E; Shallal H; Behnam Azad B; Lisok A; Pullambhatla M; Pomper MG; Nimmagadda S
Mol Pharm; 2015 Mar; 12(3):941-53. PubMed ID: 25590535
[TBL] [Abstract][Full Text] [Related]
38. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
39. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]